Subtype
Malignant Intestinal Neoplasm
CI-CAN-00001137Explore in graph →
1,666 active trials21 approved drugs383 evidence items
- NCIt
- C4572
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001137Explore in graph →
Clinical trials
7,771 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (772)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02873195 | Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer | completed | Phase 2 | 133 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT03267316 | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors(CANFOUR) | completed | Phase 1 / Phase 2 | 167 | Cantargia ABINDUSTRY | 11 | Aug 22, 2024 |
| clinicaltrials |
| NCT03981614 | Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer | completed | Phase 2 | 102 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT05086627 | Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer | completed | Phase 2 | 118 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT02743221 | A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy(TASCO1) | completed | Phase 2 | 154 | Institut de Recherches Internationales ServierOTHER | 12 | Aug 20, 2024 | clinicaltrials |
| NCT05662527 | Response to Immunotherapy in MMR-deficient Localized Colon Cancer(RESET-C) | completed | Phase 2 | 85 | Camilla QvortrupOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT00788957 | Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC) | completed | Phase 1 / Phase 2 | 177 | NantBioScience, Inc.INDUSTRY | 0 | Aug 7, 2024 | clinicaltrials |
| NCT03274882 | Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies | completed | Phase 2 | 26 | Institut de Recherches Internationales ServierOTHER | 1 | Jul 25, 2024 | clinicaltrials |
| NCT00891930 | Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab | completed | Phase 2 | 74 | NantBioScience, Inc.INDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT03217643 | CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.(EATL-001) | completed | Phase 2 | 14 | Imagine InstituteOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT06454071 | Immunologic Changes and Recovery-related Factors in Elderly Colon Cancer Patients | completed | Phase 2 | 75 | Soonchunhyang University HospitalOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT02834052 | Pembrolizumab + Poly-ICLC in MRP Colon Cancer | completed | Phase 1 / Phase 2 | 42 | Asha NayakOTHER | 1 | Jun 7, 2024 | clinicaltrials |
| NCT01851369 | TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas | completed | Phase 1 / Phase 2 | 93 | National Cancer Institute (NCI)NIH | 1 | May 8, 2024 | clinicaltrials |
| NCT02291289 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)(MODUL) | completed | Phase 2 | 1,044 | Hoffmann-La RocheINDUSTRY | 23 | May 6, 2024 | clinicaltrials |
| NCT04216251 | PRevention Using EPA Against coloREctal Cancer(PREPARE) | completed | Phase 1 / Phase 2 | 81 | Massachusetts General HospitalOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT03146962 | High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies | completed | Phase 2 | 61 | Weill Medical College of Cornell UniversityOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT04205955 | Testing Diet Intervention Versus Non-Diet Intervention for Management of Bowel Symptoms in Rectal Cancer Survivors | completed | Phase 2 | 95 | SWOG Cancer Research NetworkNETWORK | 2 | May 1, 2024 | clinicaltrials |
| NCT04124601 | Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer(CHINOREC) | completed | Phase 2 | 80 | Johannes Laengle, MD, PhDOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT04271813 | Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC) | completed | Phase 2 | 30 | Shanghai Changzheng HospitalOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT00445965 | Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer | completed | Phase 2 | 78 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT00321828 | Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 90 | NSABP Foundation IncNETWORK | 1 | Mar 21, 2024 | clinicaltrials |
| NCT03665285 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 109 | NextCure, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT00407654 | VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer | completed | Phase 2 | 75 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03530267 | Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer(ELDERLY) | completed | Phase 2 | 124 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05468892 | Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial(VELO) | completed | Phase 2 | 68 | University of Campania Luigi VanvitelliOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT02316340 | Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer | completed | Phase 2 | 42 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT02561273 | Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 54 | University of NebraskaOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT02870920 | Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer | completed | Phase 2 | 180 | Canadian Cancer Trials GroupNETWORK | 1 | Dec 8, 2023 | clinicaltrials |
| NCT03485027 | Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer | completed | Phase 2 | 43 | Fudan UniversityOTHER | 1 | Dec 8, 2023 | clinicaltrials |
| NCT02363374 | Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer(CAOAROAIO-12) | completed | Phase 2 | 311 | Prof. Dr. med. Claus RödelOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT02599324 | Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors | completed | Phase 1 / Phase 2 | 263 | Pharmacyclics LLC.INDUSTRY | 4 | Nov 18, 2023 | clinicaltrials |
| NCT03414983 | An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread(CheckMate 9X8) | completed | Phase 2 / Phase 3 | 196 | Bristol-Myers SquibbINDUSTRY | 5 | Nov 18, 2023 | clinicaltrials |
| NCT01776307 | A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer | completed | Phase 2 | 200 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 15, 2023 | clinicaltrials |
| NCT00019760 | Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver | completed | Phase 2 | — | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 31, 2023 | clinicaltrials |
| NCT03206073 | A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer | completed | Phase 1 / Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Oct 24, 2023 | clinicaltrials |
| NCT02017704 | Chemoradiation or Brachytherapy for Rectal Cancer(CORRECT) | completed | Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT02090101 | Study Evaluating the Influence of LV5FU2 Bevacizumab Plus Anakinra Association on Metastatic Colorectal Cancer(IRAFU) | completed | Phase 2 | 32 | Centre Georges Francois LeclercOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT03721653 | FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients(AtezoTRIBE) | completed | Phase 2 | 218 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT03639714 | A Study of a Personalized Neoantigen Cancer Vaccine | completed | Phase 1 / Phase 2 | 29 | Gritstone bio, Inc.INDUSTRY | 2 | Sep 13, 2023 | clinicaltrials |
| NCT03953235 | A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens | completed | Phase 1 / Phase 2 | 39 | Gritstone bio, Inc.INDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
| NCT03156036 | Preoperative CRT With Capecitabine ± Temozolomide in Patients With LARC | completed | Phase 2 | 64 | Asan Medical CenterOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT04166435 | TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer | completed | Phase 2 | 11 | Yale UniversityOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT01622543 | Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer | completed | Phase 2 | 109 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 23, 2023 | clinicaltrials |
| NCT01591421 | P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer. | completed | Phase 1 / Phase 2 | 22 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT02460198 | Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164) | completed | Phase 2 | 124 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 27, 2023 | clinicaltrials |
| NCT00578721 | Trial of Aspirin and Arginine Restriction in Colorectal Cancer | completed | Phase 2 | 24 | University of California, IrvineOTHER | 1 | Jul 7, 2023 | clinicaltrials |
| NCT03735680 | A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer | completed | Phase 2 | 30 | OncoNano Medicine, Inc.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT00098787 | Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer | completed | Phase 2 | 247 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 5, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Aug 23, 2024source: clinicaltrials